NCT02130193 - Investigation of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations | Biotech Hunter

Enrollment

102

Participants

Timeline

Start Date

February 13, 2014

Primary Completion Date

August 29, 2016

Study Completion Date

August 29, 2016

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

Danirixin

Danirixin is available as 50 or 75 mg white, film coated immediate release tablet.

DRUG

Placebo

Subjects will receive danirixin matching placebo

Trial Locations (16)

10787

GSK Investigational Site, Berlin

10789

GSK Investigational Site, Berlin

19140

GSK Investigational Site, Philadelphia

19456

GSK Investigational Site, Oaks

22927

GSK Investigational Site, Großhansdorf

29303

GSK Investigational Site, Spartanburg

35294

GSK Investigational Site, Birmingham

39112

GSK Investigational Site, Magdeburg

45359

GSK Investigational Site, Essen

52242

GSK Investigational Site, Iowa City

52349

GSK Investigational Site, Düren

60596

GSK Investigational Site, Frankfurt am Main

63263

GSK Investigational Site, Neu-Isenburg

80206

GSK Investigational Site, Denver

04207

GSK Investigational Site, Leipzig

04275

GSK Investigational Site, Leipzig